ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ACINETOBACTER SPP IN THE PERIOD 2012

Introduction. Representatives of the genus Acinetobacter have become an important cause of hospital-acquired infections due to their great ability to survive and spread in a hospital environment, as well as rapid development of resistance to many antibiotics. The aim of this study was to determine the incidence of nosocomial infections caused by Acinetobacter spp among patients hospitalized at the Clinic of Infectious Diseases of the Clinical Center of Vojvodina; determine the presence and prevalence of resistance to antimicrobials in strains Acinetobacter spp, isolated from patient materials routinely sampled at the Clinic of Infectious Diseases of the Clinical Center of Vojvodina in the period January 1, 2012 to December 31, 2015. Material and Methods. A retrospective study included 1.673 patients with infectious diseases of bacterial etiology treated at the Clinic of Infectious Diseases of the Clinical Center of Vojvodina. The analysis of blood cultures, urine, cerebrospinal fluid culture, wound/decubitus swab, throat swabs, cannula/ tube swabs, and bronchial aspirate was performed to establish the incidence of infections caused by Acinetobacter spp and antimicrobial resistance. Results. During the four-year research, Acinetobacter spp was isolated from blood samples in 14/260 (5.4%), urine in 6/198 (3.0%), cerebrospinal fluid in 2/43 (4.7%), wound/decubitus swabs in 33/128 (25.8%), throat swabs in 14/124 (11.3%) cannula/ tube swabs and bronchial aspirate in 32/72 (44.4%) samples. The isolates of Acinetobacter spp showed the highest susceptibility to colistin (100%). Resistance to carbapenems and piperacillin/tazobactam accounted for nearly 100% in all tested isolates, while resistance to other antibiotics was over 63.6%, except to tobramycin whose resistance accounted for 11.1%. Conclusion. Representatives of the genus Acinetobacter are a common cause of nosocomial infections in hospitalized patients. Acinetobacter spp is only sensitive to colistin (100%), while it is resistant in various percentages to all other tested antibiotics.

[1]  A. Peleg,et al.  Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options , 2015, Seminars in Respiratory and Critical Care Medicine.

[2]  Y. Doi,et al.  Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacterbaumannii Infections , 2014, Drugs.

[3]  Ivana Dragoslav Rosić,et al.  ANTIMIKROBNA OSETLJIVOST BAKTERIJA RODA ACINETOBAKTER IZOLOVANIH IZ INFICIRANIH RANA U TERCIJARNOJ ZDRAVSTVENOJ USTANOVI , 2013 .

[4]  Ivana Goić-Barišić.  Multiplorezistentni Acinetobacter baumannii (MRAB) – deset godina nakon pojave prvih izolata u Hrvatskoj , 2012 .

[5]  A. Hidrón,et al.  Multidrug Resistance among Gram-Negative Pathogens That Caused Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2006–2008 , 2010, Infection Control & Hospital Epidemiology.

[6]  M. Bassetti,et al.  Drug treatment for multidrug-resistant Acinetobacter baumannii infections. , 2008, Future microbiology.

[7]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[8]  P. Higgins,et al.  Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  S. Heo,et al.  Characterization of Acinetobacter baumannii carrying bla(OXA-23), bla(PER-1) and armA in a Korean hospital. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  K. Towner,et al.  Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  Arjana Tambić Andrašević.  OTPORNOST BAKTERIJA NA ANTIBIOTIKE - VODEĆI PROBLEM MEDICINE U 21. STOLJEĆU , 2007 .

[12]  S. Unal,et al.  Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. , 2005, Diagnostic microbiology and infectious disease.

[13]  L. Dijkshoorn,et al.  Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised individuals. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  J. Rodríguez-Baño,et al.  Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  P. Hsueh,et al.  Pandrug-Resistant Acinetobacter baumannii Causing Nosocomial Infections in a University Hospital, Taiwan , 2002, Emerging infectious diseases.

[16]  T. Pitt,et al.  Distribution of Acinetobacter Species on Skin of Healthy Humans , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[17]  P. Gerner-Smidt,et al.  Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods , 1997, Journal of clinical microbiology.

[18]  E Bergogne-Bérézin,et al.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features , 1996, Clinical microbiology reviews.

[19]  P. Gerner-Smidt,et al.  Reliability of phenotypic tests for identification of Acinetobacter species , 1991, Journal of clinical microbiology.

[20]  M. Aly,et al.  Incidence and Prevalence of Acinetobacter baumannii in King Fahd General Hospital , Saudi Arabia , 2013 .

[21]  Naohisa Matsunaga,et al.  [Acinetobacter spp]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[22]  Vera Gusman.  REZISTENCIJA NA KARBAPENEME KOD SOJEVA ACINETOBACTER SPP IZOLOVANIH IZ BRISEVA RANA TOKOM 2009. I 2010. GODINE CARBAPENEMS RESISTANCE OF ACINETOBACTER SPP STRAINS ISOLATED FROM WOUND SWABS DURING 2009-2010 , 2011 .

[23]  S. Gillespie,et al.  Principles and practice of clinical bacteriology , 2005 .

[24]  R. Wenzel,et al.  Annals of Clinical Microbiology and Antimicrobials Open Access Emerging Resistance among Bacterial Pathogens in the Intensive Care Unit – a European and North American Surveillance Study (2000–2002) Intensive-care Unitantibiotic Susceptibility , 2022 .